Hepatitis B virus (HBV) DNA is the key prognostic factor determining both disease activity and risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B viral infection. It is also the key viral factor in deciding when to start antiviral therapy and to monitor the response to therapy. Quantitative hepatitis B surface antigen (HBsAg) reflects the amount and the transcriptional activity of covalently closed circular DNA inside hepatocytes.1 Therefore, quantitative HBsAg provides information concerning disease activity over and above an estimation of viral replication. The enzyme immunoassays of HBsAg that are in widespread use do not quantify total circulating protein, nor do they distinguish between the different HBsAg proteins. HBsAg quantification detects all three forms of circulating HBsAg, namely the virion-associated HBsAg, subviral particles and HBsAg produced from integrated sequence. The two commercially available HBsAg quantification assays, the Architect QT assay (Abbott Laboratories, Wiesbaden, Germany) and the Elecsys HBsAg II Quant assay (Roche Diagnostic, Indianapolis, IN), give a measure of total HBsAg and have good correlation with each other.2 The clinical use of measuring quantitative HBsAg can be summarized below.